RT Journal Article
T1 SARS-CoV-2 neutralising antibody testing in Europe: towards harmonisation of neutralising antibody titres for better use of convalescent plasma and comparability of trial data.
A1 Nguyen, Dung
A1 Simmonds, Peter
A1 Steenhuis, Maurice
A1 Wouters, Elise
A1 Desmecht, Daniel
A1 Garigliany, Mutien
A1 Romano, Marta
A1 Barbezange, Cyril
A1 Maes, Piet
A1 Van Holm, Bram
A1 Mendoza, Joaquín
A1 Oyonarte, Salvador
A1 Fomsgaard, Anders
A1 Lassaunière, Ria
A1 Zusinaite, Eva
A1 Resman Rus, Katarina
A1 Avšič-Županc, Tatjana
A1 Reimerink, Johan Hj
A1 Brouwer, Fiona
A1 Hoogerwerf, Marieke
A1 Reusken, Chantal Bem
A1 Grodeland, Gunnveig
A1 Le Cam, Sophie
A1 Gallian, Pierre
A1 Amroun, Abdennour
A1 Brisbarre, Nadège
A1 Martinaud, Christophe
A1 Leparc Goffart, Isabelle
A1 Schrezenmeier, Hubert
A1 Feys, Hendrik B
A1 van der Schoot, C Ellen
A1 Harvala, Heli
K1 Europe
K1 SARS-CoV-2
K1 convalescent plasma
K1 neutralising antibodies
K1 standardisation, COVID-19
AB We compared the performance of SARS-CoV-2 neutralising antibody testing between 12 European laboratories involved in convalescent plasma trials. Raw titres differed almost 100-fold differences between laboratories when blind-testing 15 plasma samples. Calibration of titres in relation to the reference reagent and standard curve obtained by testing a dilution series reduced the inter-laboratory variability ca 10-fold. The harmonisation of neutralising antibody quantification is a vital step towards determining the protective and therapeutic levels of neutralising antibodies.
YR 2021
FD 2021
LK http://hdl.handle.net/10668/18180
UL http://hdl.handle.net/10668/18180
LA en
DS RISalud
RD Apr 6, 2025